Dr Val Tate is a Principal Associate with Cambridge Healthcare & Biotech
Val Tate has over 16 years' commercial experience in start-up, private and publicly traded biotechnology companies, holding roles in Business Development and Commercial management. This broad experience, encompassing therapeutics, diagnostics and forensics, informs her top-level, strategic advice to senior management on quality dialogue with all stakeholders, including the City, regulators, partners, the media and employees.
A background in medical communications for major international pharmaceutical companies was excellent grounding for her former role as Head of Investor Relations at London-based cancer company Antisoma, where she was a member of the IPO team and took part in subsequent fundraising rounds. She broadened this experience at NASDAQ and LSE-listed drug delivery company SkyePharma.
Val now advises clients on the formulation and articulation of company strategy through diverse media including business planning, presentations and websites. Her activities particularly support fundraising and partnering initiatives..
She is a member and former Board Director of the Investor Relations Society.
With a PhD in biochemistry, Val had an earlier international academic career, publishing widely in virology, gene structure, cloning and expression, and molecular genetics.